Statistics

Total Visits

Views
A phase II, multicenter, four-cohort study of oral cMET inhibitor capmatinib (INC280) in patients with EGFR wild-type, advanced NSCLC who have received one or two prior lines of systemic therapy for advanced/metastatic disease172

Select a period of time:

Number of views in the range

Views
A phase II, multicenter, four-cohort study of oral cMET inhibitor capmatinib (INC280) in patients with EGFR wild-type, advanced NSCLC who have received one or two prior lines of systemic therapy for advanced/metastatic disease156

Views

Views
February 20254
March 202517
April 20253
May 202571
June 202537
July 202522
August 20252
Download CSV file
 untranslated
 untranslated

Top country views

Views
Singapore122
United States16
Brazil9
United Kingdom3
Argentina1
Spain1
Italy1
Turkey1
Ukraine1
South Africa1
 

Top cities views

Views
Alfenas1
Belém1
Botucatu1
Campo Belo1
Candelária1
Chicago1
Council Bluffs1
Grottolella1
Ipiranga do Norte1
Janesville1